NM_000535.7:c.2567T>G
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PP3_Strong
The NM_000535.7(PMS2):c.2567T>G(p.Leu856Arg) variant causes a missense change involving the alteration of a conserved nucleotide. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_000535.7 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 4 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 12
GnomAD3 exomes AF: 0.00000969 AC: 2AN: 206402Hom.: 0 AF XY: 0.0000178 AC XY: 2AN XY: 112490
GnomAD4 exome AF: 0.00000668 AC: 6AN: 897626Hom.: 0 Cov.: 12 AF XY: 0.00000650 AC XY: 3AN XY: 461516
GnomAD4 genome Cov.: 12
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:2
The p.L856R variant (also known as c.2567T>G), located in coding exon 15 of the PMS2 gene, results from a T to G substitution at nucleotide position 2567. The leucine at codon 856 is replaced by arginine, an amino acid with dissimilar properties. This variant has been detected in probands whose Lynch syndrome-associated tumors demonstrated both intact expression and isolated loss of PMS2 expression by immunohistochemistry (Ambry internal data). This variant has also been detected in conjunction with a pathogenic mutation in PMS2 by our laboratory; however, the phase (whether in cis or trans) is not known. The patient's phenotype was suggestive of CMMR-D (Ambry internal data). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. -
- -
not provided Uncertain:1
Not observed at a significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Observed in an individual with cancer evaluated with MSI and IHC (Li et al., 2020); This variant is associated with the following publications: (PMID: Fukui2011[Chapter], 31391288) -
Hereditary nonpolyposis colorectal neoplasms Uncertain:1
This sequence change replaces leucine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 856 of the PMS2 protein (p.Leu856Arg). The frequency data for this variant in the population databases (gnomAD) is considered unreliable due to the presence of homologous sequence, such as pseudogenes or paralogs, in the genome. This missense change has been observed in individuals with colon cancer and/or endometrial cancer (internal data). ClinVar contains an entry for this variant (Variation ID: 142260). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt PMS2 protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Lynch syndrome 4;C5399763:Mismatch repair cancer syndrome 1 Other:1
Variant interpreted as Uncertain significance and reported on 09-24-2018 by Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at